AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
Very low LDL-C Levels Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., N...
Source: businessinsider.com
Page 3 - Michael Strapazon News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Strapazon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Strapazon Today - Breaking & Trending Today
AMGEN TO WEBCAST INVESTOR CALL AT AHA 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific...
Source: prnewswire.com
AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA
/PRNewswire/ -- (Oct. 6, 2022) – Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Francisco's Oyster Point,...
Source: prnewswire.com
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy...
Source: prnewswire.com
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in...
Source: prnewswire.com